Influenza virosomes as vaccine adjuvant and carrier system. - Wikidata - awgldk - TriplyDB

Influenza virosomes as vaccine adjuvant and carrier system.

Influenza virosomes as vaccine adjuvant and carrier system.

http://www.wikidata.org/entity/Q38124062

about

Establishment of a new quality control and vaccine safety test for influenza vaccines and adjuvants using gene expression profiling Vaccine Adjuvants: from 1920 to 2015 and Beyond Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head Safety assessment of adjuvanted vaccines: Methodological considerations Recent advances of vaccine adjuvants for infectious diseases Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza Virus Liposomes as vaccine delivery systems: a review of the recent advances.Novel antigen delivery systems.Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.Particle-based platforms for malaria vaccines.Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4+ T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen.Intranasal formulations: promising strategy to deliver vaccines.Novel therapies and vaccines against the human respiratory syncytial virus.Liposomal adjuvants for human vaccines.Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.Expression, immunogenicity and diagnostic value of envelope proteins from an Egyptian hepatitis C virus isolate.Adjuvant formulations for virus-like particle (VLP) based vaccines.Anti-Infectious Human Vaccination in Historical Perspective.Virosome engineering of colloidal particles and surfaces: bioinspired fusion to supported lipid layers.Vaccine adjuvants.Towards personalized, tumour-specific, therapeutic vaccines for cancer.Understanding modern-day vaccines: what you need to know.Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation Adjuvanted influenza vaccines

P2860

Q21131780-CB82A1DF-B4B2-4069-A0AB-14BAF58665D6 Q26783879-DAF1E8F0-07D4-48B1-A58D-6D4D41B569BB Q26783897-5D78D2A7-CACC-43C7-9004-268599B15A55 Q27013956-61672C66-FB67-49E2-ACC2-7146230D1817 Q28083679-D93C7001-87A2-4EF7-B38A-6DF5D5C0651B Q30380945-62A6DA32-1698-460D-93FC-5042A184FCE7 Q34418761-F7886479-D1C5-4F71-A2F2-E00951E606C8 Q35947894-64D70588-533F-4E3C-A3AA-69D5D6DAF057 Q36276014-4B4B9018-EA71-4B19-9286-8C49E77AAED9 Q36396040-1A96E67A-FA5A-4254-8257-7C9E81D9BCB0 Q37740679-1E391369-922A-4CF2-85D3-CBE93DD5F117 Q38223050-9E867E99-F904-4F27-B209-79E68D0B62AF Q38604787-1ACFAE90-A4E6-4C2B-9808-B33C864A013E Q38729260-9CE7A5F9-8F12-4D72-9D56-7207A0BAFD52 Q38886698-E15CD36E-D1ED-4A9F-8D7E-E1F120053BA8 Q38971243-AC4963B1-2493-43B7-9811-3BD6A3D65C23 Q39046601-3E0E4178-C7F0-4210-805E-52E6C6227C27 Q40093469-546FB857-5DA4-4562-B343-3F692FAF1358 Q40129444-171409A0-68A8-450F-9B10-FA5FBC02A655 Q40837622-163B756E-C5A4-4E64-B4D8-A73B00389426 Q44800976-7614C5D5-F799-48FA-8959-B2EA57564F5F Q47789519-DF470174-8D51-4FB6-8ADA-7CFD8CFE7BDE Q48238411-C3023059-E56D-4D02-A626-52E0BB2A85D5 Q52725104-2CA0BF03-B45A-4F1C-A186-3A98C52D7DF6 Q55432126-00707929-021E-4A5E-94AB-C3A6BE1B0EAD Q56993652-1CD58CAB-D22B-4BD0-86C1-FE2A94336812 Q57094841-CC3A3EAA-5531-4E2D-87BB-3C3498D2909B

P2860

Influenza virosomes as vaccine adjuvant and carrier system.

http://www.wikidata.org/entity/Q38124062

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Influenza virosomes as vaccine adjuvant and carrier system.

@en

type

label

Influenza virosomes as vaccine adjuvant and carrier system.

@en

prefLabel

Influenza virosomes as vaccine adjuvant and carrier system.

@en

P1433

Q38124062-A01729BA-AB98-45A1-8A29-3F81CB191D5F

P1476

Q38124062-7AE637CD-F1A3-4A37-AC44-D14DF52A347A

P2093

Q38124062-1A4599F6-B0CF-4ACB-857F-248DFC862FC8

Q38124062-6E837D53-7E72-4DD5-A05D-FDD416FEE042

Q38124062-7EEA4B3F-01B9-42AF-881C-730884D25FB1

Q38124062-91C88E89-CB31-4FA0-8D0B-317CD1D1B675

Q38124062-B23C796B-6E5E-425B-A8A9-EB4EADBD568B

P2860

Q38124062-04692767-CB6F-43B2-AB19-61E77DB980A8

Q38124062-0BD768D8-BCB1-4C5D-AA85-CD56D694E7D1

Q38124062-0CD33CE3-29F7-4828-BBC3-37DF6EC49D16

Q38124062-15DDFAAE-1554-4566-B602-EE57A32EAAF9

Q38124062-198B29E7-C5FC-44C2-8CB5-20900ABF9624

Q38124062-296C70EF-B575-41EF-83B1-E262F50072FF

Q38124062-32DDE6C8-B366-4C17-9277-87DDCDD8C908

Q38124062-38EB6F03-08E7-4D83-9542-BC1A3EF7355B

Q38124062-39DD786C-88DC-482F-A4E7-5CD9AA4E8D68

Q38124062-3B01E70F-8ECA-4034-A4CA-356122EFCF1C

P304

Q38124062-9195E907-F75F-4538-B76B-AD1233B3837A

P31

Q38124062-46AB850D-8A6D-4534-98BA-BFC7DD549107

P356

Q38124062-0CAC168C-A339-4188-9B4A-1B1B7D81DBE6

P433

Q38124062-FAE97769-6CC2-4DDB-9911-926FF92895F3

P478

Q38124062-369CAE1B-F21A-4130-8459-ADF1E6E88FEC

P577

Q38124062-97C7D433-619D-4B57-9C5A-4D6337AA6A85

P5875

Q38124062-6E584DB7-B0C3-4A4F-A859-E415148A7BBE

P698

Q38124062-D2C217E9-8F65-46E3-9A57-C67B8D747223

P356

14760584.2013.811195

P1433

Expert Review of Vaccines

P1476

Influenza virosomes as vaccine adjuvant and carrier system.

@en

P2093

Christian Moser

http://www.w3.org/2001/XMLSchema#string

Mario Amacker

http://www.w3.org/2001/XMLSchema#string

Matthias D Kaeser

http://www.w3.org/2001/XMLSchema#string

Matthias Müller

http://www.w3.org/2001/XMLSchema#string

Ulrike Weydemann

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP

Pseudovirions as vehicles for the delivery of siRNA

The virosome concept for influenza vaccines

Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice

Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children

Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.

Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.

A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers

A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.

P304

779-791

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14760584.2013.811195

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

253651220

http://www.w3.org/2001/XMLSchema#string

P698

23885823

http://www.w3.org/2001/XMLSchema#string